Barclays PLC Acquires 182,138 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Barclays PLC raised its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 69.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 445,795 shares of the company's stock after buying an additional 182,138 shares during the quarter. Barclays PLC owned 0.22% of Cellebrite DI worth $9,821,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CLBT. R Squared Ltd acquired a new position in Cellebrite DI in the 4th quarter valued at $100,000. Polen Capital Management LLC acquired a new position in Cellebrite DI in the 4th quarter valued at $222,000. Victory Capital Management Inc. acquired a new position in Cellebrite DI in the 4th quarter valued at $234,000. HighTower Advisors LLC acquired a new position in Cellebrite DI in the 4th quarter valued at $274,000. Finally, Pictet Asset Management Holding SA acquired a new position in Cellebrite DI in the 4th quarter valued at $283,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Price Performance

Shares of CLBT stock traded up $0.14 on Monday, hitting $19.78. 608,985 shares of the company's stock were exchanged, compared to its average volume of 1,412,070. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The stock has a market cap of $4.74 billion, a P/E ratio of -14.23, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The company has a 50 day moving average of $18.73 and a 200 day moving average of $20.15.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Lake Street Capital increased their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of "Buy" and a consensus target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.